- Company
- KIPO, IPTAB to introduce ‘advance invalidation notice’
- by Hwang, byoung woo Sep 9, 2025 06:13am
- The Korean Intellectual Property Office (KIPO) and the Intellectual Property Trial and Appeal Board (IPTAB) announced a reform plan introducing a pre-announcement system for invalidation decisions (“advance invalidation notice”) in patent invalidation trials, dividing opinions within the pharmaceutical industry. Led by the Korea Pharmace
- Company
- Interest in Wegovy and Mounjaro rises at KSSO conference
- by Kim, Jin-Gu Sep 9, 2025 06:12am
- On the morning of September 5 at Conrad Hotel, Yeongdeungpo, Seoul, a long line formed in front of the registration desk for the Autumn Conference of the Korean Society for the Study of Obesity (KSSO). With more than 1,000 pre-registered attendees, the conference drew continuous interest from healthcare professionals from the very first day
- Company
- "Effect of Bavencio on long-term survival confirmed"
- by Son, Hyung Min Sep 9, 2025 06:12am
- At the conference held in Korea, Bavencio's real-world data (RWD) have been unveiled, extending beyond its initial trial that served as the basis for approval. Bavencio maintenance therapy has been shown to prolong the lives of patients with urothelial carcinoma in multiple countries, including Korea, Japan, France, and the U.S. Notably, the
- Company
- Bispecific Ab 'Epkinly' for DLBCL available at gen hospitals
- by Eo, Yun-Ho Sep 8, 2025 06:17am
- 'Epkinly,' a new innovative drug that is a T-cell-engaging bispecific antibody, is now available for prescription at general hospitals. According to industry sources, AbbVie Korea's Epkinly (epcoritamab), the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), passed the drug committees (DC) of tertiary general hosp
- Company
- Competitiveness of K-anticancer drugs reaffirmed
- by Son, Hyung Min Sep 8, 2025 06:17am
- Korean pharmaceutical companies gathered in one place to show off their anti-cancer pipelines, including both in-house developed and imported new drugs. At the Korean Society of Medical Oncology 2025 International Conference (KSMO 2025), which was held over three days from September 3 at Walkerhill Hotel in Seoul, major domestic pharmaceu
- Company
- Kerendia+Jardiance combo demonstrates early benefit
- by Hwang, byoung woo Sep 8, 2025 06:16am
- Kerendia (finerenone), a treatment for chronic kidney disease, has strengthened its clinical presence by demonstrating efficacy in combination with the SGLT-2 inhibitor Jardiance (empagliflozin). Kerendia is the first non-steroidal mineralocorticoid receptor antagonist (MRA), with a novel mechanism of action that directly suppresses infla
- Company
- Zynyz receives orphan drug designation in Korea
- by Eo, Yun-Ho Sep 5, 2025 06:20am
- The immuno-oncology drug Zynyz that Handok has decided to market in Korea has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced the designation through a public notice. Specifically, the drug is indicated for ▲Merkel cell carcinoma and ▲ squamous cell carcinoma of the anal canal (SCAC
- Company
- MenQuadfi’s indication includes infants as young as 6 weeks
- by Hwang, byoung woo Sep 5, 2025 06:19am
- On the 4th, Sanofi Kore announced that its fully liquid quadrivalent meningococcal vaccine, MenQuadfi, received expanded indication approval from the Ministry of Food and Drug Safety (MFDS) on August 26. The new approval allows MenQuadfi’s vaccination for infants from 6 weeks to under 2 years of age. With the indication extension, MenQua
- Company
- HK Inno.N and Pfizer partner to distribute COVID-19 vaccine
- by Lee, Seok-Jun Sep 5, 2025 06:18am
- HK inno.N (CEO Dal-Won Kwak) announced on the 4th that it has signed a co-promotion agreement with Pfizer Korea (CEO Dong-Wook Oh) for the 2025&8211;2026 season distribution of the new COVID-19 variant vaccine, Comirnaty LP.8.1 Prefilled Syringe (SARS-CoV-2 mRNA Vaccine), as part of the National Immunization Program (NIP). Last year, H
- Company
- Fruzaqla may be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Sep 4, 2025 06:12am
- ] The new colon cancer drug Fruzaqla is may now be prescribed at general hospitals in Korea. According to industry sources, Fruzaqla (fruquintinib), a colorectal cancer therapy from Takeda Korea that selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, 2, and 3, has passed the drug committees (DC) of 41 major medica
